Table 3 Response to the first 2... | American Society of Hematology

Table 3

Response to the first 2 treatment cycles

	All patients (n = 268)	Arm A (n = 135)	Arm B (n = 133)	P
Hematologic CR, n (%)	254 (94.8)	133 (98.5)	121 (91.0)	.006
After cycle 1	249	131	118	.009
After cycle 2	5	2	3	.68
Refractory ALL after cycle 2, n (%)	4 (1.5)	1 (0.7)	3 (2.2)	.37
MMolR, n/tested (%)
After cycle 1	96/217 (44.2)	50/116 (43.1)	46/101 (45.5)	.78
After cycle 2	134/205 (65.4)	74/112 (66.1)	60/93 (64.5)	.88
Molecular CR, n/tested (%)
After cycle 1	21/217 (9.7)	11/116 (9.5)	10/101 (9.9)	.99
After cycle 2	53/205 (25.8)	32/112 (28.6)	21/93 (22.6)	.34
Induction deaths, n (%)
Early deaths*	10 (3.7)	1 (0.7)	9 (6.7)	.010
Day 60 mortality†	15 (5.6)	3 (2.2)	12 (9.0)	.017

	All patients (n = 268)	Arm A (n = 135)	Arm B (n = 133)	P
Hematologic CR, n (%)	254 (94.8)	133 (98.5)	121 (91.0)	.006
After cycle 1	249	131	118	.009
After cycle 2	5	2	3	.68
Refractory ALL after cycle 2, n (%)	4 (1.5)	1 (0.7)	3 (2.2)	.37
MMolR, n/tested (%)
After cycle 1	96/217 (44.2)	50/116 (43.1)	46/101 (45.5)	.78
After cycle 2	134/205 (65.4)	74/112 (66.1)	60/93 (64.5)	.88
Molecular CR, n/tested (%)
After cycle 1	21/217 (9.7)	11/116 (9.5)	10/101 (9.9)	.99
After cycle 2	53/205 (25.8)	32/112 (28.6)	21/93 (22.6)	.34
Induction deaths, n (%)
Early deaths*	10 (3.7)	1 (0.7)	9 (6.7)	.010
Day 60 mortality†	15 (5.6)	3 (2.2)	12 (9.0)	.017

Early death was defined as death occurring during cycle 1 or 2, before the assessment of hematologic response after cycle 1 or 2.

Five patients died in CR before day 60 (2 in arm A and 3 in arm B).